PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930094
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930094
mRNA Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of mRNA vaccines Market
The global mRNA vaccines market is rapidly transforming the pharmaceutical and biotechnology landscape, supported by technological innovation, strong research investments, and expanding therapeutic applications beyond COVID-19. According to Fortune Business Insights, the market was valued at USD 6.01 billion in 2025 and is projected to grow from USD 6.85 billion in 2026 to USD 25.64 billion by 2034, registering a strong CAGR of 17.94% during the forecast period. In 2025, North America dominated the market with a 31.47% share, driven by advanced healthcare infrastructure and strong R&D activity.
Market Overview
mRNA (messenger RNA) vaccines work by instructing cells to produce proteins that trigger an immune response. Unlike traditional vaccines, mRNA platforms enable faster development, higher flexibility, and scalable manufacturing. The successful deployment of COVID-19 mRNA vaccines marked a turning point for the market and validated the technology's potential across multiple disease areas, including infectious diseases, autoimmune disorders, and oncology.
Technological advancements, including the integration of artificial intelligence (AI) tools in vaccine development and clinical trials, have further accelerated innovation. Key players such as Moderna Inc., Pfizer Inc., BioNTech, CureVac SE, and GSK plc are heavily investing in research to expand their mRNA vaccine pipelines.
Market Size Highlights
- 2025 Market Size: USD 6.01 billion
- 2026 Market Size: USD 6.85 billion
- 2034 Market Size: USD 25.64 billion
- CAGR (2026-2034): 17.94%
The market's rapid growth reflects increasing confidence in mRNA technology following its global validation during the COVID-19 pandemic.
Market Drivers
A major driver of market growth is the increase in R&D activities focused on mRNA-based vaccines. The success of COVID-19 vaccines has encouraged pharmaceutical companies and governments to explore mRNA platforms for influenza, RSV, HIV, and other infectious diseases. Public and private sector investments continue to rise to support innovation.
For instance, Moderna announced plans to invest approximately USD 25 billion in R&D from 2024 to 2028, aimed at expanding its mRNA medicine portfolio. Additionally, AI-powered tools, such as Pfizer's Smart Data Query (SDQ), have improved clinical trial efficiency, reducing development timelines and supporting faster market entry.
Market Restraints and Challenges
Despite strong growth prospects, the market faces challenges from a stringent regulatory landscape. Regulatory approval for mRNA vaccines outside emergency scenarios involves complex processes, including IND and BLA submissions, which may delay commercialization. Manufacturing complexities, cold-chain storage requirements, and large-scale production constraints also hinder growth, especially in low-resource regions.
Another key challenge is vaccine hesitancy, driven by misinformation and safety concerns. Variations in vaccine acceptance across regions can limit uptake, particularly for booster doses and newly developed mRNA vaccines.
Market Opportunities
The expanding applications of mRNA vaccines beyond COVID-19 present significant growth opportunities. Several candidates targeting RSV, influenza, malaria, and autoimmune diseases are currently in the clinical pipeline. The flexibility of mRNA platforms allows rapid adaptation to emerging pathogens, making them highly valuable for future pandemic preparedness.
Additionally, increasing collaborations between pharmaceutical companies and global health organizations are accelerating innovation. Partnerships such as BioNTech's collaboration with CEPI for neglected diseases highlight the growing scope of mRNA technology.
Segmentation Insights
By type, COVID-19 vaccines dominated the market, as they were the first approved mRNA-based products. However, non-COVID-19 vaccines are expected to grow rapidly, supported by pipeline expansion. By indication, COVID-19 infection held the dominant share, while RSV vaccines show strong future potential following recent regulatory approvals. By distribution channel, hospital and retail pharmacies accounted for a significant share, supported by government vaccination programs.
Regional Outlook
North America led the market, with a valuation of USD 1.89 billion in 2025 and USD 2.28 billion in 2026, driven by strong R&D infrastructure and government investments. Europe ranked second, supported by favorable policies and research institutions. Asia Pacific is expected to grow substantially, fueled by rising infectious disease prevalence, increasing clinical trials, and expanding biotechnology investments. The rest of the world is witnessing steady growth due to improved access initiatives and regional manufacturing expansions.
Competitive Landscape
The market is highly concentrated, with Pfizer Inc., Moderna Inc., and BioNTech holding significant shares. These companies continue to strengthen their positions through product innovation, strategic collaborations, and pipeline expansion. Other notable players include CureVac SE, GSK plc, Sanofi, and Arcturus Therapeutics.
Conclusion
In conclusion, the global mRNA vaccines market is poised for robust and sustained growth, expanding from USD 6.01 billion in 2025 to USD 25.64 billion by 2034. Continuous R&D investments, technological advancements, and expanding therapeutic applications are driving market momentum. While regulatory complexities and vaccine hesitancy pose challenges, the proven success and adaptability of mRNA technology position it as a cornerstone of future vaccine development worldwide.
Segmentation By Type
- COVID-19 Vaccines
- Non-COVID-19 Vaccines
By Indication
- COVID-19 Infection
- Respiratory Syncytial Virus (RSV) Infection
- Others
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Indication, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Indication, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Indication, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Rest of the World (By Type, Indication, and Distribution Channel)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. New Product Launches, By Key Players
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Technological Advancements in the mRNA Vaccines Market
- 4.4. Incidence/Prevalence of Key Diseases, 2025
- 4.5. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
5. Global mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. COVID-19 Vaccines
- 5.1.2. Non-COVID-19 Vaccines
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. COVID-19 Infection
- 5.2.2. Respiratory syncytial virus (RSV) Infection
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital & Retail Pharmacies
- 5.3.2. Government Suppliers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
6. North America mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. COVID-19 Vaccines
- 6.1.2. Non-COVID-19 Vaccines
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. COVID-19 Infection
- 6.2.2. Respiratory syncytial virus (RSV) Infection
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital & Retail Pharmacies
- 6.3.2. Government Suppliers
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. COVID-19 Vaccines
- 7.1.2. Non-COVID-19 Vaccines
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. COVID-19 Infection
- 7.2.2. Respiratory syncytial virus (RSV) Infection
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital & Retail Pharmacies
- 7.3.2. Government Suppliers
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. COVID-19 Vaccines
- 8.1.2. Non-COVID-19 Vaccines
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. COVID-19 Infection
- 8.2.2. Respiratory syncytial virus (RSV) Infection
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital & Retail Pharmacies
- 8.3.2. Government Suppliers
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Rest of the World mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. COVID-19 Vaccines
- 9.1.2. Non-COVID-19 Vaccines
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. COVID-19 Infection
- 9.2.2. Respiratory syncytial virus (RSV) Infection
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital & Retail Pharmacies
- 9.3.2. Government Suppliers
- 9.3.3. Others
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 10.2.1. Moderna Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Products & services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. BioNTech
- 10.2.2.1. Overview
- 10.2.2.2. Products & services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. CureVac SE
- 10.2.3.1. Overview
- 10.2.3.2. Products & services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. GSK plc
- 10.2.4.1. Overview
- 10.2.4.2. Products & services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Sanofi
- 10.2.5.1. Overview
- 10.2.5.2. Products & services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Pfizer Inc.
- 10.2.6.1. Overview
- 10.2.6.2. Products & services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Gennova Biopharmaceuticals Limited
- 10.2.7.1. Overview
- 10.2.7.2. Products & services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Walvax Biotechnology Co., Ltd.
- 10.2.8.1. Overview
- 10.2.8.2. Products & services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Arcturus Therapeutics
- 10.2.9.1. Overview
- 10.2.9.2. Products & services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.1. Moderna Inc.
List of Tables
- Table 1: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 3: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 6: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 7: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America mRNA Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 10: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 11: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 14: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 15: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 18: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 19: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a
List of Figures
- Figure 1: Global mRNA Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global mRNA Vaccines Market Value Share (%), by Type, 2025 & 2034
- Figure 3: Global mRNA Vaccines Market Value Share (%), by Indication, 2025 & 2034
- Figure 4: Global mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 5: Global mRNA Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 6: North America mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 7: North America mRNA Vaccines Market Value Share (%), by Type, 2025
- Figure 8: North America mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
- Figure 9: North America mRNA Vaccines Market Value Share (%), by Indication, 2025
- Figure 10: North America mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: North America mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America mRNA Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 13: North America mRNA Vaccines Market Value Share (%), By Country, 2025
- Figure 14: Europe mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 15: Europe mRNA Vaccines Market Value Share (%), by Type, 2025
- Figure 16: Europe mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
- Figure 17: Europe mRNA Vaccines Market Value Share (%), by Indication, 2025
- Figure 18: Europe mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 19: Europe mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 21: Europe mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 23: Asia Pacific mRNA Vaccines Market Value Share (%), by Type, 2025
- Figure 24: Asia Pacific mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
- Figure 25: Asia Pacific mRNA Vaccines Market Value Share (%), by Indication, 2025
- Figure 26: Asia Pacific mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 27: Asia Pacific mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 29: Asia Pacific mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 30: Rest of the World mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 31: Rest of the World mRNA Vaccines Market Value Share (%), by Type, 2025
- Figure 32: Rest of the World mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
- Figure 33: Rest of the World mRNA Vaccines Market Value Share (%), by Indication, 2025
- Figure 34: Rest of the World mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 35: Rest of the World mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Global mRNA Vaccines Market Share (%), By Company, 2025
